Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03916081 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT03916081 is a Phase 2 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 136 participants.
The verdict
NCT03916081, a Phase 2 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic dermatitis.
Interventions
- DRUG Vehicle Cream
- DRUG Roflumilast Cream 0.15%
- DRUG Roflumilast Cream 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2019-05-31 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03916081
The ClinicalTrials.gov registry entry for NCT03916081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle Cream is the first listed.
NCT03916081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03916081 about?
NCT03916081 is a clinical study titled "Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis". The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic dermatitis.
What is the current status of trial NCT03916081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2019-05-31. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT03916081?
The interventions under investigation include: Vehicle Cream (DRUG), Roflumilast Cream 0.15% (DRUG), Roflumilast Cream 0.05% (DRUG).
Who is sponsoring clinical trial NCT03916081?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.